A comparison of regression discontinuity and propensity score matching to estimate the causal effects of statins using electronic health records

Michelle C. Odden, PhD[1], Adina Zhang, MS[2], Neal Jawadekar, MPH[2], Annabel Tan, MPH[1], Adina Zeki Al Hazzouri, PhD[2], Sebastian Calonico, PhD[3]

Author's affiliations:

1. Department of Epidemiology and Population Health, Stanford University, Stanford, CA
2. Department of Epidemiology, Columbia University, New York, NY
3. Department of Health Policy and Management, Columbia University, New York, NY

Corresponding Author:

Michelle C. Odden, PhD

Associate Professor

Dept. of Epidemiology & Pop. Health

Stanford University School of Medicine

HRP Redwood Building, Rm T259

259 Campus Drive

Stanford, CA 94305-5405

(650) 721-0230

modden@stanford.edu

Abstract:

Background: Regression discontinuity is gaining popularity in epidemiologic studies aimed at causal inference from observational data, but there are limited real-world studies comparing this approach to potential outcomes methods.

Methods: In this methodologic investigation, we estimate the causal effect of statins on myocardial infarction (MI), a positive control outcome, using regression discontinuity and propensity score matching. For the regression discontinuity analysis, we leveraged a 2008 UK guideline that recommends statins if a patient's 10-year cardiovascular disease (CVD) risk score >20%. We used electronic health record data (2008-2018) from the Health Improvement Network (THIN) on 49,242 patients aged 65 and older in the UK without a history of CVD and no statin use in the year prior to the CVD risk score assessment. Outcomes were defined using Read codes and censored at 10 years; 10-year CVD risk was assessed primarily (81.8%) using the 1991 Framingham risk score.

Results: In sex and age adjusted analyses, the estimate for statin use on MI was HR = 2.69 (95% CI: 2.28, 3.17). Both the regression discontinuity (n=19,432) and the propensity score matched populations (n=24,814) demonstrated good balance of confounders. Using regression discontinuity, the adjusted point estimate for statins on MI was in the protective direction, although the confidence interval included the null (HR: 0.79, 95% CI: 0.44, 1.44). Conversely, the adjusted estimates using propensity score matching remained in the harmful direction: HR = 2.41 (95% CI: 1.96, 2.99).

Conclusion: Regression discontinuity appeared superior to propensity score matching in estimation of the known protective association of statins with MI, although precision was poor. A strength of

regression discontinuity is that it can better account for bias due to unmeasured confounders than matching, which is of key importance in observational studies aimed at causal inference.

There is increasing use of quasi-experimental designs in epidemiologic studies aimed at deriving causal estimates from observational data. Regression discontinuity designs leverage clinical or policy decision rules in which people fall on either side of a threshold or cut-point.(1) The assumption is that persons falling just above or below the threshold are exchangeable, and thus causal estimates can be made near this threshold. This is a distinct approach from propensity score matching, which aims to model the probability of treatment and then match observations based on this probability, thus enhancing exchangeability.(2) These methods are both of interest in pharmacoepidemiology studies where the goal is to estimate treatment benefits and harms, based on observational data. Observational studies can be biased by confounding by indication, where users of a therapy may be less healthy than non-users, because of the indication for treatment. Conversely, healthy user bias can also confound estimates of association, as users of preventive therapies may be healthier than non-users due to other health-seeking behaviors. Regression discontinuity and propensity score matching can address confounding by indication and health user bias. Yet, applied examples comparing these two approaches in pharmacoepidemiologic investigations are limited, and thus researchers lack practical guidance for their implementation.

Statins (HMG-CoA reductase inhibitors) are a widely used class of lipid-lowering medications with demonstrated cardiovascular benefits. A large meta-analysis of randomized statin treatment trials found a relative risk of 0.73 (95% CI: 0.67, 0.80) for fatal or non-fatal coronary heart disease events.(3) Statin benefits may be slightly attenuated among older users, as the PROSPER trial among adults 72-80 years found a hazard ratio of myocardial infarction of 0.81 (95% CI: 0.69, 0.94).(4) In addition, a recent subgroup analysis of the ALLHAT-LTT trial aged 65 and older reported a hazard ratio of 0.80 (95% CI: 0.62, 1.04) for coronary heart disease events.(5)

In 2008, the National Institute for Health and Care Excellence in the United Kingdom (UK) recommended that statins are indicated for the primary prevention of cardiovascular disease (CVD) if a patient's 10-year risk for fatal or nonfatal CVD, calculated based on a combination of demographic and clinical factors, is greater than or equal to 20%.(6) This national-level guideline provides an ideal setting for a regression discontinuity study design (1) because the treatment is given or withheld only according to the CVD risk score, thus patients just below and above the 20% cutoff are likely to have similar characteristics. In the present study, we compare the estimates for the effects of statins on myocardial infarction (MI) by a regression discontinuity design and propensity score matching in British adults 65 years and older using a large database of UK electronic health records. We selected MI as a positive control outcome since the benefit of statins on this outcome are well described. For contrast, we used motor vehicle accidents as a negative control outcome; statin use is not causally associated with this outcome. The goals of this investigation were twofold. First, we aimed to evaluate the performance of a regression discontinuity design on estimating known casual effects. Second, we compared the findings to those from a propensity-score matched analysis, which aims to account for predictors of treatment. Our results underscore the strengths and limitations of both approaches in an applied setting.

Methods:

Study Population

The IQVIA Medical Research Data contains de-identified electronic health record data from general practitioner practices contributing to the Health Improvement Network (THIN) database in the United Kingdom. This research database includes approximately 11 million patients and covers more than 5% of the total population and is representative of the UK general practice population.(7) A detailed description has been presented elsewhere.(8, 9) THIN data collection began in 2003 and includes a rich collection of variables and diagnoses including demographic information, medical diagnoses (including referrals to specialists), prescriptions, laboratory results, lifestyle factors, measurements taken during medical practice, and free text comments. Data recorded in THIN is very accurate and subject to several assurance procedures.(10-12) Consultation and prescription rates recorded in the THIN database have been shown to be comparable with published national data estimates.(13) Furthermore, the validity of the prescription data for epidemiological research has been demonstrated.(10) In particular, associations between various drugs and outcomes in THIN have shown to be similar, in direction and magnitude, to the associations observed in other UK medical records databases.(10)

Given that the statins guideline was issued in 2008, we set the baseline period for our study as 2008-2011. Our initial sample included 85,152 patients aged 65 years and older with an assessment of their CVD risk score recorded anytime during the years 2008-2011. (Figure 1) We then excluded patients who were registered in the THIN database for <6 months prior to their CVD risk score assessment (n = 5,133), in order to ensure adequate data on their health history. We also excluded those who had a statin prescription in 2 years prior to their CVD risk score assessment, to mimic the washout period of a new user design. Finally, we excluded persons with a history of CVD prior to their CVD risk score assessment (n = 381) as the CVD risk score is intended for persons without a history of events.

Assessment of 10-year CVD Risk Score: Running Variable

We used the first CVD risk-score recorded in our study baseline (2008-2011). We included Framingham 10-year CVD risk, QRISK, and QRISK2 scores, which are all prediction algorithms for CVD disease.(14-16) Of 49,242 participants, 40,259 (81.8%) had CVD risk recorded using the Framingham score. A total of 257 patients had two scores recorded on the same day so we averaged the two. (eTable 1)

Assessment of Statin Initiation: Treatment

Prescription data is recorded using codes from the UK pricing authority.(17) Statin initiation was defined as a new prescription in a patient with no prior statin prescription in the prior two years.

Assessment of MI and Motor Vehicle Accident: Outcomes

Symptoms and diagnoses are entered using a system of Read codes, a coding system that can be mapped onto ICD-10 codes.(18, 19)The primary outcome of interest was fatal and non-fatal acute myocardial infarction (MI). Events were identified from the list of Read codes provided by IQVIA and cross-checked with members of our study team (MCO, AEM): 323..00, 323Z.00, G30..00, G300.00, G301.00, G301000, G301100, G30..12, G30..13, G30..15, G30..16, G30..17, G301z00, G302.00, G303.00, G304.00, G305.00, G306.00, G307.00, G307000, G307100, G308.00, G309.00, G30B.00, G30X.00, G30X000, G30y.00, 30y100, G30y200, G30yz00, G30z.00, G311000, G311011, G35..00, G350.00, G351.00, G353.00, G35X.00, G360.00, G362.00, G363.00, G364.00, G365.00, G38..00, G380.00, G381.00, G384.00, G38z.00, Gyu3400, Gyu3600. The secondary outcome was injury resulting from motor vehicle accidents, identified from the Medical file using Read codes beginning with T1.

Other Measures

Demographic data including age, sex, and marital status. The Townsend score (presented in quintiles) is an area-level measure of deprivation derived from Census data. Additional variables included physical activity (low, moderate, high), smoking status, BMI, diabetes, and hypertension status. For all covariates, we used baseline values recorded prior to the patient's CVD risk score.

Statistical Analysis

We compared three different modeling approaches in the statistical analysis: a regression discontinuity model, a traditional multivariable adjusted Cox proportional hazards model, and a propensity score matched Cox proportional hazards model. All models were censored at 5 years of follow-up.

For our regression discontinuity analysis, we estimated the treatment effect of statin use on incident MI using a sharp regression discontinuity for Cox models. The treatment of interest in this design is the eligibility for statin treatment although we note that not all eligible persons were prescribed statins, and vice versa. We use the CVD risk score as the running variable, with a cutoff of 20% determining which statin treatment was presumed as prescribed/withheld. In that sense, a sharp regression discontinuity resembles an intent to treat analysis as participants above the cutoff are assumed to have initiated statins, and those below the cutoff are assumed to have not initiated statins.(20) In addition to the running variable and the cutoff, we selected a bandwidth of 5.0%. The bandwidth, which indicates how far above and below the cutoff to go in order to define our regression discontinuity sample, was chosen based on standard methods balancing the bias and variance of the regression discontinuity estimation.(21, 22) We explored the sensitivity of the findings to the bandwidth. Among those who were eligible for our regression discontinuity experiment, only a total of 19,432 patients were then included in our local regression discontinuity sample determined by the bandwidth. Next, using the same bandwidth, we examined covariate balance around the 20% cutoff in key confounders including age,

sex, marital status, Townsend score, smoking status, physical activity, BMI, diabetes, and hypertension. We first ran unadjusted regression discontinuity Cox models, we then adjusted for potential confounders. Hazard ratios and 95% confidence intervals were calculated using robust standard errors.

Next, we estimated a traditional sex and age-adjusted and multivariable adjusted Cox proportional hazards model. This was conducted in the full sample size of patients who met our eligibility criteria; n=49,242. As such, we examined the relationship of statins initiation in 2008-2011 with incident MI outcomes through 2018, adjusting for the same set of potential confounders as were used in the regression discontinuity model.

Last, we performed a propensity score matching analysis, where we modeled the probability for initiating statins as a function of the same set of confounders. Propensity scores for treatment and control groups were matched one-to-one using the nearest neighbor method. The matched treatment groups were checked for variable balance in their propensity score distributions and absolute mean differences in the matched sample (n=24,814). We then ran a Cox model on the new matched data evaluating the relationship of statins initiation with MI outcomes, unadjusted and then adjusted for the same confounders.

We explored injuries from motor vehicle accidents as a negative control outcome, however bandwidth calibration revealed the sensitivity of these results to the selection of the bandwidth, so we did not pursue this outcome in regression discontinuity or Cox models.

R version 4.0.3 with tidyverse, rdrobust version 0.99.5,(23) survival version 3.2-7 and MatchIt packages were used for the analyses.

Results:

The cohort of 49,242 patients who met our inclusion criteria had a mean age of 69.8 years (SD 4.2) and a little over half were female (56.1%). (Table 1) The majority were nonsmokers, and about a third each had normal, obese, and very obese BMI. Nearly half had hypertension (43.2%) and only 2.4% were diabetic. Most patients had 10-year CVD risk assessed by the 1991 Framingham risk score, and the mean score was 23% (median = 21.8%). (eTable 1) Among the 21,326 participants who had a 10-year CVD risk score below 20%, 11.9% initiated statins by the end of 2011. Among the 12,114 patients who had a 10-year CVD risk score at 20% or above, 35.4% initiated statins by the end of 2011. (eTable 2)

Potential confounders were balanced using a regression discontinuity design with a bandwidth of 5.0% (n=18,718), and the confidence intervals for the differences above and below the 20% CVD risk score cutoff included the null, with the exception of missing Townsend and physical activity data. (Table 2)

Propensity scores ranged from 0.07 to 0.65 before matching and 0.46 to 0.61 after matching (eFigure 1). A total of 12,412 pairs were matched for a matched analysis sample size of 24,814. Before matching, female sex, smoking status, and BMI were most imbalanced among statin users and non-users. (Figure 2) After matching, all absolute mean differences in covariates were less than 0.05. (Figure 2)

Among the 49,242 eligible patients, 665 (1.2%) had an MI over the next 5 years. The algorithm selected a bandwidth of 5.0 and we observed that the HR of MI was robust around this value (eFIgure2). Based on a regression discontinuity model, the association was in the protective direction, although the confidence interval included the null; the adjusted regression discontinuity Cox model estimate was 0.79 (95% CI: 0.44, 1.43). (Table 3) In contrast, based on traditional Cox models, the estimate was in the harmful direction (adjusted HR = 2.51, 95%CI: 2.12, 2.97). Results from propensity score matching did

not meaningfully differ from the standard Cox estimates: the adjusted propensity score matched Cox

model HR estimate was 2.41 (95% CI: 1.96-2.99). (Table 2)

As exploratory analyses, we evaluated the regression discontinuity model Cox model at different lengths

of follow-up and found a stronger effect at 2 years (0.58, 95% CI: 0.22, 1.57) that attenuated towards

the null at 10 years (0.96, 95% CI: 0.59, 1.54).

Only 205 injuries due to motor vehicle accidents were recorded in 5 years (0.4%). The HR at the

algorithm selected bandwidth (4.85) suggested a protective effect of statin, although the confidence

interval crossed the null. The effect size and confidence intervals were highly variable around this

bandwidth so we did not pursue this outcome further. (eFigure 2)

Discussion:

In summary, regression discontinuity appeared superior to propensity score matching in estimation of the known protective association of statins with MI, although precision was limited. Regression discontinuity analysis resulted in point estimates similar to those from randomized controlled trials whereas matching did not. Unadjusted analyses showed an increased risk of MI among statin users, likely due to confounding by indication. Both regression discontinuity design and propensity score matching achieved good balance of measured confounders, but our finding that regression discontinuity methods achieve estimates nearing those from trials, which are in the range of a relative risk of 0.7 to 0.8.(3-5) The performance of the regression discontinuity design suggests that this approach may account for bias in unmeasured confounders. However, the lack of precision of the estimates remained a serious limitation.

Our study is builds on other studies that have demonstrated the application of regression discontinuity design in pharmacoepidemiology studies of statin use. Geneletti and O'Keeffe and others have previously validated the regression discontinuity design to estimate causal effects when applied to estimate the effect of statins on low density lipoprotein cholesterol concentration for people around the 20% CVD risk threshold in the THIN database.(24, 25) They demonstrated a protective effect of statins on low density lipoprotein cholesterol using regression discontinuity estimates of the average treatment effect, although the effect size was smaller than observed in randomized controlled trials. Using simulation studies, they showed that regression discontinuity estimators were attenuated towards the null in simulations with high unmeasured confounding and non-compliance with the guideline. Our investigation extends this work by evaluating two hard outcomes, MI and motor vehicle accidents, and comparing the findings to a propensity score matched analysis. Although we do not know the true

confounding structure in our data, our estimates likely represent an underestimation of the treatment effects of statin use.

Our study provides a real-world application of regression discontinuity estimation in a pharmacoepidemiologic study, leveraging a national guideline on wider statins use in the UK. The implementation of the guideline provides a unique advantage to estimating causality relative to the US, which does not have a national health care system and is subject to more heterogeneity in practice at the health care system, clinic, and provider level. However, our study also has limitations that should be considered. Electronic health records are subject to misclassification bias. Although previous studies have demonstrated a high degree of validity in THIN data, (10-12) there may still be residual measurement error. Because we used electronic health record data, we had limited information on socioeconomic status. We used the Townsend deprivation score, which is an area-level score indicated socioeconomic status based on Census data. However, we had no individual-level measures of socioeconomic status. Additionally, this study was conducted in the UK and may not generalize to other populations. However, we have no reason to believe that the biological effects of statins would vary by population.

A major challenge was that event rates were lower than in trials, which are often over sampled for high-risk participants. Thus, even with a large sample size, we had a modest number of events and precision of the estimates was limited. The limited number of negative control events, injuries due to a motor vehicle accident, precluded us from using this as an outcome. Finally, we used a sharp regression discontinuity design, which assumes that those above the cutpoint initiated statins and those below the cutpoint did not. However, we observed empirically that many deviated from this rule. A fuzzy RD design would relax this assumption allowing for non-compliance. However, methods that incorporates a fuzzy

regression discontinuity design into a Cox model are not available, and this is an ongoing area of methodologic development.

In summary, regression discontinuity appears to be a promising approach to control for measured and unmeasured confounding in observational pharmacoepidemiologic studies. Future methods development that relax the assumption of compliance and combine fuzzy design and time-to-event models would be beneficial.

Funding:

This work was funded by R56-AG061177 from the National Institute on Aging.

References:

1. Venkataramani AS, Bor J, Jena AB. Regression discontinuity designs in healthcare research. *BMJ* 2016;352:i1216.
2. Rosenbaum PR, Rubin DB. The Central Role of the Propensity Score in Observational Studies for Causal Effects. *Biometrika* 1983;70(1):41-55.
3. Cholesterol Treatment Trialists C, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet* 2010;376(9753):1670-81.
4. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet* 2002;360(9346):1623-30.
5. Han BH, Sutin D, Williamson JD, et al. Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial. *JAMA Intern Med* 2017;177(7):955-65.
6. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation study. *Heart* 2008;94(1):34-9.
7. Blak BT, Thompson M, Dattani H, et al. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. *Inform Prim Care* 2011;19(4):251-5.
8. Danaei G, Garcia Rodriguez LA, Fernandez Cantero O, et al. Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival. *Diabetes Care* 2013;36(5):1236-40.
9. Smeeth L, Douglas I, Hall AJ, et al. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. *Br J Clin Pharmacol* 2009;67(1):99-109.
10. Lewis JD, Schinnar R, Bilker WB, et al. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. *Pharmacoepidemiol Drug Saf* 2007;16(4):393-401.
11. Maguire A, Blak BT, Thompson M. The importance of defining periods of complete mortality reporting for research using automated data from primary care. *Pharmacoepidemiol Drug Saf* 2009;18(1):76-83.
12. Ruigomez A, Martin-Merino E, Rodriguez LA. Validation of ischemic cerebrovascular diagnoses in the health improvement network (THIN). *Pharmacoepidemiol Drug Saf* 2010;19(6):579-85.
13. Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. *Inform Prim Care* 2004;12:171-7.
14. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. *Am Heart J* 1991;121(1 Pt 2):293-8.
15. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. *BMJ* 2007;335(7611):136.
16. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. *BMJ* 2008;336(7659):1475-82.
17. Garcia Rodriguez LA, Perez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. *Br J Clin Pharmacol* 1998;45(5):419-25.
18. Dave S, Petersen I. Creating medical and drug code lists to identify cases in primary care databases. *Pharmacoepidemiol Drug Saf* 2009;18(8):704-7.
19. Chisholm J. The Read clinical classification. *BMJ* 1990;300(6732):1092.

20.   Calonico S, Cattaneo MD, Titiunik R. Robust Nonparametric Confidence Intervals for Regression-Discontinuity Designs. *Econometrica* 2014;82(6):2295-326.
21.   Calonico S, Cattaneo MD, Farrell MH. On the Effect of Bias Estimation on Coverage Accuracy in Nonparametric Inference. *J Am Stat Assoc* 2018;113(522):767-79.
22.   Imbens G, Kalyanaraman K. Optimal Bandwidth Choice for the Regression Discontinuity Estimator. *Rev Econ Stud* 2012;79(3):933-59.
23.   Calonico S, Cattaneo MD, Farrell MH, et al. rdrobust: Software for regression-discontinuity designs. *Stata J* 2017;17(2):372-404.
24.   Geneletti S, O'Keeffe AG, Sharples LD, et al. Bayesian regression discontinuity designs: incorporating clinical knowledge in the causal analysis of primary care data. *Stat Med* 2015;34(15):2334-52.
25.   O'Keeffe AG, Geneletti S, Baio G, et al. Regression discontinuity designs: an approach to the evaluation of treatment efficacy in primary care using observational data. *BMJ* 2014;349:g5293.
26.   Dormuth CR, Patrick AR, Shrank WH, et al. Statin adherence and risk of accidents: a cautionary tale. *Circulation* 2009;119(15):2051-7.

Results:

Table 1: Baseline characteristics of participants at time of CVD-risk score assessment

	Overall
N	N=49,242
Age, years (Mean, SD)	69.8 (4.2)
Sex (N, %)	
Male	21,625 (43.9)
Female	27,617 (56.1)
Marital Status* (N, %)	
Partnered	2,187 (4.4)
Single	9,473 (19.2)
Missing	37,582 (76.3)
Smoking Status (N, %)	
Not currently smoking	42,986 (87.3)
Currently smoking	6,085 (12.4)
Missing	171 (0.3)
Physical Activity (N, %)	
Moderate activity or less	14,292 (29.0)
High activity	2,279 (4.6)
Missing	32,671 (66.3)
Townsend Score (N, %)	
Lowest 3 quintiles	34,436 (69.9)
Upper 2 quintiles	9,794 (19.9)
Missing	5,012 (10.2)
BMI Categories (N, %)	
Less than 25 kg/m^2	16,550 (33.6)
25-30 kg/m^2	19,720 (40.0)
30-35 kg/m^2	8,084 (16.4)
35+ kg/m^2	3,023 (6.1)
Missing	1,865 (3.8)
Hypertension (N, %)	
No	27,968 (56.8)
Yes	21,274 (43.2)
Diabetes (N, %)	
No	48,042 (97.6)
Yes	1,200 (2.4)

*partnered includes married, co-habiting, stable relationship; single includes single, widowed, divorced, separated

Table 2: Balance of key confounders above and below the 20% CVD risk score threshold, using a regression discontinuity design*

Variable	N	N <20%| ≥20% risk	Coefficient[†]	Confidence Interval	p-value
Age, years	18,718	9,670 | 9,048	-0.139	-0.362, 0.329	0.93
Sex (Female vs Male)	18,718	9,670 | 9,048	-0.030	-0.082, 0.003	0.07
Marital status (Partnered vs Single)	4,509	2,432 | 2,077	0.024	-0.056, 0.080	0.73
Marital status missing	18,718	9,670 | 9,048	0.001	-0.028, 0.048	0.59
Townsend Score (4th - 5th vs 1st-3rd quintile)	16,934	8,785 | 8,149	0.012	-0.035, 0.043	0.84
Townsend Missing	18,718	9,670 | 9,048	0.018	0.002, 0.054	0.03
Smoking Status (Current vs. Not current)	18,666	9,646 | 9,020	0.007	-0.009, 0.035	0.24
Smoking Status Missing	18,718	9,670 | 9,048	0.002	0.000, 0.010	0.05
Physical activity (High vs Low/moderate)	6,380	3,346 | 3,034	0.030	-0.007, 0.105	0.09
Physical Activity Missing	18,718	9,670 | 9,048	-0.030	-0.108, -0.026	0.001
BMI kg/m^2	18,116	9,393 | 8,723	-0.087	-0.413, 0.441	0.95
BMI Missing	18,718	9,670 | 9,048	0.003	-0.010, 0.023	0.45
Diabetes	18,718	9,670 | 9,048	-0.005	-0.016, 0.002	0.15
Hypertension	18,718	9,670 | 9,048	-0.008	-0.046, 0.042	0.92

*This sample was restricted to those within the bandwidth of 5.0

[†]Represents above minus below the cutoff

Table 3: A comparison of estimates of the association of statins initiation (2008-2011) and incident MI over 5 years, based on different analytic approaches

Model	N	HR	Confidence Interval	p-value
Regression Discontinuity Model*				
Sex, Age adjusted	19,432	0.80	0.44, 1.44	0.45
Fully[†] adjusted	19,432	0.79	0.44, 1.43	0.44
Traditional Cox Model				
Sex, Age adjusted	49,242	2.69	2.28, 3.17	<0.001*
Fully[†] adjusted	49,242	2.51	2.12, 2.97	<0.001*
Cox Model in Propensity Score Matched Subset				
Sex, Age adjusted	24,814	2.44	1.97, 3.01	<0.001*
Fully[†] adjusted	24,814	2.41	1.96, 2.99	<0.001*

*This sample was restricted to those within the bandwidth of 5.0

[†]Adjusted for age, sex, marital status, Townsend score, smoking, physical activity, BMI, hypertension, diabetes.

Figure 1: Consort flow diagram for the study population

Figure 2: Standardized absolute difference in key confounders after matching

Supplemental Material:

eTable 1: Summary of CVD Risk Scores by Type

	N	Mean	SD
1991 Framingham 10-year	40,259	23.5	10.60
QRISK	2,868	22.4	9.69
QRISK2	5,858	21.1	10.0
Multiple Scores	257	22.7	9.08

eTable 2: Adherence below and above the 20% CVD risk score cutoff

	Below 20%	Above 20%
Total	21,326	27,916
Not Prescribed Statins	**18,788 (88.1%)**	18,047 (64.6%)
Prescribed Statins	2,538 (11.9%)	**9,869 (35.4%)**

eTable 3: Regression discontinuity estimates of the association of statins initiation (2008-2011) and incident MI over 2, 5, and 10 years

	2-year	5-year	10-year
HR (95% CI)	0.58 (0.22, 1.57)	0.80 (0.44, 1.44)	0.96 (0.59, 1.54)
P-value	0.28	0.45	0.86
N	19,432	19,432	19,432
# of Events	62	172	263

eFigure 1: Histograms of propensity scores before and after matching

eFigure 2. Bandwidth calibration illustrates bandwidth on X-axis and HR for MI (left) and injury resulting from motor vehicle accidents (MVA) (right) over 5 years